


Ask a doctor about a prescription for EBASTINE FORTE STADA 20 mg ORALLY DISINTEGRATING TABLETS
Patient Information Leaflet
Ebastina Forte Flas Stada 20 mg Oral Dispersible Tablets EFG
Read this entire leaflet carefully before starting to take this medicine, as it contains important information for you.
Contents of the Leaflet
Ebastina is a medicine used to treat allergies (antihistamine). It helps control the symptoms of an allergic reaction.
It is indicated in adults and children aged 12 years or older for the treatment of seasonal or perennial allergic rhinitis (hay fever) with or without allergic conjunctivitis (eye inflammation), and for the treatment of urticaria (hives) in adults over 18 years of age.
Do not take Ebastina Forte Flas Stada
Warnings and precautions
Consult your doctor or pharmacist before taking Ebastina Forte Flas Stada:
Children and adolescents
Ebastina should only be used by children aged 12 years or older, as its safety and efficacy have not been established in this age group.
Taking Ebastina Forte Flas Stada with other medicines
Tell your doctor or pharmacist that you are taking, have recently taken, or may need to take any other medicine.
Ebastina may affect or be affected by other medicines that contain the following active substances:
Taking Ebastina Forte Flas Stada with food and drinks
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.
Pregnancy
Breastfeeding
Driving and using machines
Ebastina Forte Flas Stada contains sodium
This medicine contains less than 23 mg of sodium (1 mmol) per oral dispersible tablet; this is, essentially "sodium-free".
Follow the instructions for administration of this medicine exactly as indicated by your doctor. If you are unsure, consult your doctor or pharmacist again.
The recommended dose is:
For the treatment of allergic rhinitis (hay fever) with or without allergic conjunctivitis (eye inflammation)
For adults and adolescents aged 12 years or older:
Use in children and adolescents
Ebastina should not be used in children under 12 years of age.
Patients with renal insufficiency
Patients with renal insufficiency do not need to adjust the dose.
Patients with severe liver insufficiency
The dose should not exceed 10 mg in these patients.
Patients with mild to moderate liver insufficiency
Patients with mild to moderate liver insufficiency do not need to adjust the dose.
Method of administration
Duration of treatment
Your doctor will decide the duration of treatment with ebastina.
If you take more Ebastina Forte Flas Stada than you should
If you forget to take Ebastina Forte Flas Stada
Do not take a double dose to make up for forgotten doses. Take the next dose at the usual time.
If you have any other questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone gets them.
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Rare (may affect up to 1 in 1,000 people)
Unknown frequency (cannot be estimated from the available data)
Reporting of side effects
If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
This medicine does not require special storage conditions.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date stated on the carton after EXP. The expiration date is the last day of the month indicated.
Medicines should not be disposed of via wastewater or household waste. Dispose of the packaging and any unused medicine in the SIGRE collection point at your pharmacy. Ask your pharmacist how to dispose of the packaging and any unused medicine. This will help protect the environment.
Composition of Ebastina Forte Flas Stada
*Composition: natural flavoring, identical natural flavoring, acacia gum (E-414), maltodextrin, sodium benzoate (E-211), butylated hydroxyanisole (E-320).
Appearance of the product and package contents
Ebastina Forte Flas Stada 20 mg are oral dispersible tablets, white to off-white, round, flat with beveled edges, approximately 11 mm in diameter and 2.70 mm in thickness, marked on one side with "20" and smooth on the other side.
The oral dispersible tablets are packaged in peelable OPA/Alu/PVC - Paper/PET/Alu blisters.
Ebastina Forte Flas Stada 20 mg is available in cartons containing 20 and 30 oral dispersible tablets.
Not all pack sizes may be marketed.
Marketing authorization holder and manufacturer
Marketing authorization holder
Laboratorio STADA, S.L.
Frederic Mompou, 5
08960 Sant Just Desvern (Barcelona)
Spain
Manufacturer
STADA Arzneimittel AG
Stadastrasse 2-18
61118 Bad Vilbel
Germany
or
Meiji Pharma Spain, S.A.
Avda. de Madrid, 94
28802 Alcalá de Henares (Madrid)
Spain
This medicine is authorized in the Member States of the European Economic Area under the following names:
Netherlands: NOTAXO 20 mg, orodispersible tablet
Italy: Ebastina EG 20 mg, orodispersible tablet
Spain: Ebastina Forte Flas Stada 20 mg oral dispersible tablets EFG
Date of the last revision of this leaflet:July 2019
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
The average price of EBASTINE FORTE STADA 20 mg ORALLY DISINTEGRATING TABLETS in November, 2025 is around 8.79 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for EBASTINE FORTE STADA 20 mg ORALLY DISINTEGRATING TABLETS – subject to medical assessment and local rules.